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Among DNA damages, double-strand breaks (DSBs) are one of the most harmful lesions to a cell. Failure in
DSB repair could lead to genomic instability and cancer. Homologous recombination (HR) and nonhomolo-
gous end joining (NHEJ) are major DSB repair pathways in higher eukaryotes. It is known that expression
of DSB repair genes is altered in various cancers. Activation of DSB repair genes is one of the reasons
for chemo- and radioresistance. Therefore, targeting DSB repair is an attractive strategy to eliminate cancer.
Besides, therapeutic agents introduce breaks in the genome as an intermediate. Therefore, blocking the
residual repair using inhibitors can potentiate the efficacy of cancer treatment. In this review, we discuss
the importance of targeting DSB repair pathways for the treatment of cancer. Recent advances in the devel-
opment of DSB repair inhibitors and their clinical relevance are also addressed.Maintenance of genomic integrity is critical for the survival of an
organism. Multiple DNA repair pathways act in an orchestrated
manner to protect our genome from a variety of genotoxic
stresses. Besides DNA repair, the genetic information is pro-
tected by processes such as cell cycle checkpoints and apo-
ptosis. There are various types of DNA damage that perturb
the primary structure of DNA. Examples include pyrimidine di-
mers, mismatches, crosslinks, single-strand breaks, and dou-
ble-strand breaks (DSBs) (Sancar et al., 2004). Among DNA
damages, DSBs are considered to be lethal DNA lesions within
the cells. Misrepaired DSBs can lead to chromosomal rearrange-
ments such as translocations and deletions, resulting in onco-
genic transformation or cell death (Nambiar and Raghavan,
2011; Zhu et al., 2002).
In a cell, DSBs can be generated by physiological or patho-
logical means. Various physiological processes, such as V(D)J
recombination, class switch recombination, or meiosis, generate
DSBs as intermediates (Lieber, 2010). Apart from this, DSBs can
be produced by ionizing radiation, oxidative free radicals, repli-
cation across a nick, or inadvertent enzyme actions such as
abortive topoisomerase II activity (Hutchinson, 1985; Sordet
et al., 2009; Valerie and Povirk, 2003).
Higher eukaryotes possess two major DNA double-strand
break repair pathways, homologous recombination (HR) and
nonhomologous DNA end joining (NHEJ) (Pardo et al., 2009).
HR requires extensive homology for the repair of DNA DSBs,
whereas NHEJ utilizes limited or no homology for end joining.
During the S and G2 phases of the cell cycle, HR plays a major
role in the repair of DSBs because of the presence of homolo-
gous donor sister chromatids in close proximity. In contrast,
NHEJ can operate throughout the cell cycle in higher eukaryotes
(Mao et al., 2008; Symington and Gautier, 2011).
DNA Double-Strand Break Repair Pathways
Homologous Recombination
Homologous recombination has three major steps: presynapsis,
synapsis, and postsynapsis. During the presynaptic process, a
DSB is recognized and processed to give rise to an overhangChemistry & Biolwith a 30 hydroxyl end (Figure 1) (Wyman et al., 2004). An EXO1
or MRE11-RAD50-NBS1 (MRN) complex consisting of MRE11-
RAD50-NBS1 possesses 30-50 exonuclease activity, which re-
sects the DNA ends to generate such 30 single-stranded tails
(Paull and Gellert, 1998, 1999). Besides, helicase-nuclease com-
plexes of Bloom helicase (BLM)/DNA replication helicase/
nuclease 2, bipolar nuclease (DNA2) in the presence of replica-
tion protein A (RPA) reinforces 50-30 resection polarity (Chen
et al., 2013; Nimonkar et al., 2011). Furthermore, EXO1 activity
during resection can also be stimulated in the presence of
BLM and RPA. Both resection mechanisms are stimulated by
the MRN complex and generate extensively resected DNA
ends (Nimonkar et al., 2011).
During synapsis, DNA strand invasion takes place by the
RAD51-single stranded DNA (ssDNA) filament to generate a D
loop (Li and Heyer, 2008; Paull and Gellert, 1998; Sancar et al.,
2004) (Figure 1). RPA, which is a single-strand binding protein,
can enhance strand exchange by sequestering protein-free
single-stranded DNA and also destabilize secondary structure
formation, allowing contiguousRAD51-ssDNAnucleofilament for-
mation. Binding of RAD51 to ssDNA by nucleation, a kinetically
slower process, can also be impeded by RPA (Carreira and Ko-
walczykowski, 2011). This inhibitory effect can be overcome
by BRCA2 along with other recombinase accessory factors
(also termed recombination mediators) (Seong et al., 2009). The
RAD51 paralog RAD52 interacts directly with RPA, which allows
transfer of ssDNA from RPA to RAD52, therefore facilitating the
nucleation of RAD51 onto the RPA-coated ssDNA (New et al.,
1998). Besides its recombination mediator activity, RAD52 also
helps in RAD51 independent single-strand annealing (SSA). SSA
takes place when breaks are flanked by regions of 30 to several
hundred base pair-long homologies (McVey and Lee, 2008). Dur-
ing SSA, RAD52 can align the RPA-coated single-stranded DNA
after resection, followed by flap removal by ERCC1/XPF (San Fil-
ippo et al., 2008; Valerie and Povirk, 2003). Another RAD51 pa-
ralog, RAD54, which is a dsDNA-dependent ATPase, is important
for the turnover of the RAD51-dsDNA complex and facilitates
strand invasion during HR (Solinger et al., 2002).ogy 22, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 17
Figure 1. Mechanism of Homologous Recombination-Mediated
DNA Double-Strand Break Repair
During homologous recombination, DSBs are recognized and resected by the
MRN complex to generate a 30 overhang. BRCA2/RAD51, along with other
RAD51 paralogs, binds to the ssDNA tails, forming a presynaptic filament.
Upon strand invasion, D loop formation takes place, after which three inde-
pendent pathways can operate, depending on second end capture (double-
strand break repair), disengagement of the strand after synthesis (SDSA),
multiple invasions, synthesis, and disengagements (BIR).
Figure 2. Mechanism of Nonhomologous DNA End Joining in
Humans
During NHEJ, the KU70/80 heterodimer is recruited to the DSB ends, pro-
tecting them from further nucleolytic action, and helps in the recruitment of
downstream proteins. Autophosphorylation of the DNA-PK catalytic subunit
activates DNA-PK. The DNA-PKcs/Artemis complex can act as an endonu-
clease, which processes the DSBs. Strand synthesis in NHEJ is carried out by
Pol m and Pol l. At the final step, the Ligase IV/XRCC4/XLF complex is re-
cruited to the DNA ends to seal the processed DNA ends.
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formation of a D loop intermediate (Figure 1). In the first mode,
both ends of DSBs are engaged, either by independent strand in-
vasion or by second end capture, leading to double-strand Holli-
day junction formation (Szostak et al., 1983). The junction can be
processed by a resolvase (MUS81-EME1/SLX1-SLX4/GEN1)
into either noncrossover or crossover products. Alternatively, it
can be dissolved by a mechanism involving BLM-mediated
branch migration and TOPOIIIa and RMI1-RMI2 (RecQ-medi-
ated genome instability 1/2) and catalyzed dissolution of a hemi-
catenane, leading exclusively to noncrossover products (Wu and
Hickson, 2003; Boddy et al., 2001; Fricke and Brill, 2003; Ip et al.,
2008). In synthesis-dependent strand annealing (SDSA), the
invading strand is disengaged after DNA synthesis and annealed
with the second end, leading to localized conversion without
crossover (San Filippo et al., 2008). In break-induced replication
(BIR), the D loop is assembled into a full replication fork, copying
the entire distal part of the chromosome and resulting in loss of
heterozygosity (San Filippo et al., 2008).
NHEJ
NHEJ is a predominant DNA double-strand break repair pathway
in the mammalian system. Proteins involved in NHEJ have
greater mechanistic flexibility compared with their counterparts
in different repair processes. This enables NHEJ to provide
diverse junctional outcomes despite starting from identical ends.
During NHEJ, the KU heterodimer, consisting of KU70 and
KU80, binds to the DNA ends and protects them from nucleolytic
action on DSBs (Figure 2; Jeggo et al., 1999; Mimori et al., 1986).
KU is a toroidal protein, and its subunits form an asymmetric ring.
This channel then accommodates the double-stranded DNA
(Downs and Jackson, 2004; Walker et al., 2001; Figure 2).18 Chemistry & Biology 22, January 22, 2015 ª2015 Elsevier Ltd All rDNA-dependent protein kinase (DNA-PKcs), a nuclear protein ki-
nase (Carter et al., 1990), is phosphorylated in a DNA-dependent
manner, and it further phosphorylates several target proteins,
including Artemis (Carter et al., 1990; Morozov et al., 1994).
Artemis is one of the recently identified NHEJ components
(Moshous et al., 2001). It forms a complex with DNA-PKcs in
the absence of DNA. Although Artemis alone can act as a single
strand-specific 50/ 30 exonuclease, in complex with DNA-PKcs
it acquires endonucleolytic activity (Figure 2; Ma et al., 2002).
Synthesis during NHEJ is carried out by Pol X family polymer-
ases, among which Pol m or Pol l have been implicated in NHEJ,
whereas terminal deoxynucleotidyl transferase is found to be
important during V(D)J recombination (Bertocci et al., 2006;
Lieber, 2010). Pol m and Pol l can incorporate deoxynucleotide
triphosphates (dNTPs) and ribonucleotide triphosphates in a
template-dependent manner, whereas Pol m has the ability to
synthesize in a template-independent manner as well (Gu
et al., 2007; Nick McElhinny et al., 2005; Nick McElhinny and
Ramsden, 2003).
Ligation during NHEJ is carried out by the Ligase IV/XRCC4/
XLF complex, which exhibits an extensive mechanistic flexibility
in joining because it can ligate across gaps and noncompatible
DNA ends (Figure 2; Gu et al., 2007; Lieber, 2010; Sharma and
Raghavan, 2010). Ligase IV is the most recently identified ligase
and is unique in terms of catalyzing the nuclear DSB repair NHEJ
(Grawunder et al., 1997; Wei et al., 1995; Wilson et al., 1997). The
specific role of Ligase IV in NHEJ could be explained through its
interacting partners. By coimmunoprecipitation studies, it has
been shown that Ligase IV interacts exclusively with the
BRCA1 carboxyl terminus (BRCT) homology domain of XRCC4
(Critchlow et al., 1997; Ellenberger and Tomkinson, 2008;ights reserved
Figure 3. Choice between DNA Double-
Strand Break Repair Pathways
Selection of the mode of the DNA double-strand
break repair pathway, NHEJ, and HR is deter-
mined by various regulatory mechanisms. HR is
predominant in S and G2 phases of the cell cycle
because of the proximity of the sister chromatid.
NHEJ is active throughout the cell cycle, playing a
major role during G1 and M phases. Negative
regulation of Rif1 versus 53BP1 also commits
repair to HR or NHEJ. End resection by Mre11
and/or EXO I/BLM produces a long 30 single-
stranded tail, facilitating HR, whereas binding of
KU to DNA ends can repair directly via NHEJ. CtIP
phosphorylation through S phase of the cell cycle,
and complex formation with BRCA1 can facilitate
HR. Cell cycle-dependent kinases can also influ-
ence the repair outcomes. The regulators can
pose as potential therapeutic targets.
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that XRCC4 stimulates the joining activity of Ligase IV and is
required for its stabilization (Bryans et al., 1999; Grawunder
et al., 1997; Wilson et al., 1997). The most recently discovered
NHEJ protein XLF, upon forming a complex with Ligase IV/
XRCC4, significantly promotes the ligation of mismatched and
noncompatible DNA ends (Tsai et al., 2007).
Alternative NHEJ
Until recently, HR and NHEJ were considered to be the major
DSB repair pathways within the cell. However, recent findings
have recognized a distinct pathway that can operate at a basal
level in the absence of classical NHEJ (Boboila et al., 2010).
Although alternative NHEJ (A-NHEJ) has been reported in cells
deficient in core NHEJ proteins, it appears that A-NHEJ operates
even in NHEJ-proficient cells (Truong et al., 2013; Sharma and
Raghavan, 2010). One of the important features of A-NHEJ is
its ability to utilize short terminal microhomology regions for
joining. Therefore, it is also known as microhomology-mediated
end joining (MMEJ). However, the use of microhomology is not
an absolute requirement during A-NHEJ. Several researchers
in the field believe MMEJ to be an entirely distinct repair
pathway.
The protein machinery responsible for alternative NHEJ is not
completely characterized, and it is difficult to allocate stepwise
functional attributes to proteins at the moment. Various studies
suggest that the MRN complex, CtIP, PARP1, Ligase III, or
Ligase I are involved in A-NHEJ (Della-Maria et al., 2011; Gos-
tissa et al., 2011; Simsek and Jasin, 2010).
It appears that end recognition during alternative NHEJ can be
attributed to PARP1. It has been shown that PARP1 competes
with the KU proteins for binding to the DSB ends and can act
as a determinant for selection of the pathway. It has to be taken
into consideration that the affinity of KU proteins to the DSB
ends is ten times higher than that of PARP1. This can probablyChemistry & Biology 22, January 22, 201explain the lower occurrence of alternative
NHEJ in classical NHEJ-proficient cells
(Paddock et al., 2011; Wang et al., 2006).
However, the regulation of A-NHEJ during
microhomology search, recognition, and
end bridging or synapsis of DNA ends is
still unclear. Longer deletions associatedwith A-NHEJ can be a result of end resection during a microho-
mology search dependent on MRE11 and CtIP (Lee-Theilen
et al., 2011; Rass et al., 2009; Xie et al., 2009). The endonuclease
ERCC1/XPF,which is important for nucleotide excision repair and
interstrand crosslink repair, has also been suggested to play a role
in KU-independent end joining (Ahmad et al., 2008). Ligase III/
XRCC1 has been implicated at the step of ligation in A-NHEJ
(Simsek et al., 2011). However, recent studies suggest that Ligase
I is also important for A-NHEJ and that both ligasesmay act inter-
changeably (Paul et al., 2013). Adding to the complexity, it has
also been proposed that Ligase III might be important for micro-
homology-mediated alternative NHEJ, whereas Ligase I may
facilitate microhomology-independent A-NHEJ (Simsek et al.,
2011). However, what determines their differential loading has
not yet been explored. Despite promiscuity at themachinery level,
it has been well demonstrated that the alternative NHEJ pathway
is error-prone and may contribute to genomic instability and can-
cer (Corneo et al., 2007; Gostissa et al., 2011; Simsek and Jasin,
2010; Yan et al., 2007).
Choice between DSB Repair Pathways
Both NHEJ and HR are required for the repair of DNA double-
strand breaks. The cell cycle phase, end resection, and DSB
end structures are the major factors governing the choice be-
tween the pathways (Figure 3).
The cell cycle is one of the major factors among all of the reg-
ulatory mechanisms. HR is active in postreplicative stages of S
phase because of the availability of the homologous template
in the proximity or generation of replication associated one-
ended DSBs, which are repaired exclusively by HR (Figure 3).
Besides, the condensed chromatin structure makes a homology
search in G2-M phase challenging and, hence, restricts HR. Cell
cycle dependency of these repair pathways is believed to be
dependent upon cyclin-dependent kinases (CDKs), which5 ª2015 Elsevier Ltd All rights reserved 19
Table 1. Summary of the Effect of Knockouts of Important HR and NHEJ Genes
DSB Repair Genes Repair Pathway Phenotype of Knockouts References
ATM HR/NHEJ viable, ataxia telangiectasia
and aging syndrome
Barlow et al., 1996
ATR HR/NHEJ early embryonic lethal Brown and Baltimore, 2000; Xiao and Weaver, 1997;
Luo et al., 1999; Zhu et al., 2001MRN HR very early embryonic lethal
RAD51 HR early embryonic lethal Sonoda et al., 1998
RAD51 paralogs HR nearly normal phenotype Rijkers et al., 1998; Essers et al., 1997
BRCA1/ BRCA2 HR in utero lethal Evers and Jonkers, 2006
KU70/80 NHEJ viable, progeria Zhu et al., 1996; Vogel et al., 1999; Karanjawala et al.,
2002
DNA-PKcs NHEJ viable, SCID Taccioli et al., 1998
Artemis NHEJ viable, RS-SCID Rooney et al., 2002
Ligase IV NHEJ embryonic lethal Barnes et al., 1998; Frank et al., 2000
XRCC4 NHEJ embryonic lethal Gao et al., 2000
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phase of the cell cycle, DSBs activate phosphoinositide 3-kinase
related kinases (PI3KKs), DNA-PKcs, and ataxia telangiectasia
mutated (ATM). DSBs that are not repaired in G1 phase can
result in replication stall or fork collapse, which, upon resection,
activate the ATR-mediated checkpoint (Branzei and Foiani,
2008). These PI3KKs act as sensors of DSBs and, upon activa-
tion, initiate the signaling cascade, which helps in the recruitment
of DNA repair proteins.
Nucleolytic degradation of the 50 strand of DSBs giving rise to
the 30 ssDNA tail is referred to as 50-30 resection, and it commits
the repair pathway to HR because long 30 single-stranded DNA-
containing substrates are less favored for KU binding (Shibata
et al., 2014). The kinetics of DSB repair by HR are slow, and turn-
over of DSBs indicates the choice of NHEJ or HR. More recent
studies suggest that NHEJ is the major DSB repair pathway in
the G0, G1, and early S phases of the cell cycle and continues
to play a minor role in late S and G2 phases. Recently, it has
been uncovered that phosphorylation of 53BP1 and its effector
Rif1 inhibits BRCA1 recruitment at G1 phase of the cell cycle,
leading to inhibition of end resection andHR (Figure 3); Chapman
et al., 2013; Zimmermann and de Lange, 2014). CDK1-mediated
phosphorylation of CtIP during S and G2 phases removes this in-
hibition, thereby promoting HR (Yun and Hiom, 2009). Cancer
cells are known to possess aberrations in various checkpoint
proteins, providing them with survival advantages. In combina-
tion, knowledge of defects in DNA repair pathways and their
selection in different phases of the cell cycle opens a vast oppor-
tunity for exploring their potential as therapeutic targets.
Unlike classical NHEJ, alternative NHEJ displays slower
kinetics of repair, which explains why the former, when active,
is the predominant branch of DNA end joining. Besides, KU70
and KU80 are abundant proteins in nuclei and quickly load
onto the broken DNA ends, hence committing repair toward
NHEJ (Fattah et al., 2010).
Outcomes of Defects In DNA Double-Strand Break
Repair Pathways
Because this review deals with the therapeutic interventions of
DNA double-strand break repair proteins to target cancers, it is20 Chemistry & Biology 22, January 22, 2015 ª2015 Elsevier Ltd All rimportant to gain insights from the consequences of the com-
plete absence of such proteins. It not only provides us with
important hints about the association of repair proteins with can-
cer but also warns against the potential side effects caused by
repair inhibitors. Several repair knockout mouse models show
developmental defects, indicating that there are many functions
for repair proteins, which we have just begun to understand. In
this regard, it should be noted that the chemical inhibition of a
repair protein or pathway presents an entirely different scenario
and that is different from gene knockouts. Chemical inhibitions
are for shorter durations and can be given in a localized manner.
The HR and NHEJ pathways are not completely mutually
exclusive because one cannot substitute for defects in the other.
It has been shown thatRAD51/ cells possess higher number of
chromosomal breaks (Sonoda et al., 1998). However, knockouts
of the RAD51 paralogs RAD52 and RAD54 exhibit nearly normal
phenotypes (Essers et al., 1997; Rijkers et al., 1998). The BRCA1
gene is important for normal development, and homozygousmu-
tation of the allele results in in utero lethality of mice. Mutations in
BRCA1 and BRCA2 have been largely responsible for the
hereditary susceptibility to ovarian and breast cancer (Table 1;
Evers and Jonkers, 2006). ATR is an essential gene, and its
homozygous deletion is embryonic lethal. In contrast, ATM
knockoutmice are viable but possess growth defects and an inci-
denceof cancer (Barlowet al., 1996;BrownandBaltimore, 2000).
Knockouts of the MRN complex are also early embryonic lethal
(Luo et al., 1999; Xiao and Weaver, 1997; Zhu et al., 2001).
Ligase IV has an essential function, and the independent tar-
geted knockouts of Ligase IV and XRCC4 are embryonic lethal
(Table 1; Barnes et al., 1998). It has also been shown that besides
defective development, Ligase IV knockout mice undergo p53-
mediated apoptosis in neurons to cause embryonic lethality
(Frank et al., 2000; Gao et al., 2000). However, knockout mice
of other NHEJ proteins, such as KU, are viable but display fea-
tures of progeria (Table 1; Karanjawala et al., 2002; Taccioli
et al., 1998; Vogel et al., 1999; Zhu et al., 1996). Knockout of
Artemis shows a severe combined immunodeficiency (SCID)
phenotype with impairment in the formation of coding joints dur-
ing V(D)J recombination (Rooney et al., 2002). A specialized
function of KU and DNA-PKcs has been reported in maintainingights reserved
Figure 4. HR and NHEJ Proteins and Their Associated Defects in
Various Cancers
Defects in core NHEJ proteins such as KU, DNA-PKcs, and Ligase IV/XRCC4
and HR proteins have been implicated in a vast repertoire of cancers. The red
box denotes overexpression of the particular protein, green depicts loss
of function, and blue refers to other reasons, such as polymorphisms, muta-
tions, etc.
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of these proteins result in the shortening of telomere ends,
whereas Ligase IV was involved in joining of deprotected telo-
mere ends, driving genomic instability (d’Adda di Fagagna
et al., 2001; Hsu et al., 1999; Smogorzewska et al., 2002).
Taken together, it is evident that Ligase IV, which functions at
the last step of NHEJ, is crucial for the repair of DNA double-
strand breaks. This also highlights the fact that DSBs, which
are funneled through NHEJ until the step of ligation, cannot be
directed to alternative DSB repair pathways. Besides, cells
derived from patients with mutations or altered levels of key
NHEJ proteins such as KU, DNA-PKcs, XRCC4, and Ligase IV
are radiosensitive and can cause predisposition to cancer (Mar-
angoni et al., 2000; Riballo et al., 1999; van der Burg et al., 2009).
This also suggests that these pathways play a major role in re-
stricting chromosomal translocations and other genomic rear-
rangements, which can lead to cancer.
Many genetic disorders have also shown a predisposition to
cancer along with neurological and immunological conditions.
Examples include ataxia telangiectasia, ataxia telangiectasia-
like disorder, Nijmegen breakage syndrome, and Seckel syn-
drome, in which defective ATM,MRE11, NBS1, and ATR genes,
respectively, have been observed (Shiloh, 1997; Wyman and Ka-
naar, 2006). Apart from these, Ligase IV, Artemis, and XLF have
also been implicated in Ligase IV syndrome, radiosensitive (RS)
SCID, and immunodeficiency, respectively (Rass et al., 2007).
Cells defective in the repair genes show sensitivity toward
many genotoxic agents. This property of cancer cells has been
exploited during radio- and chemotherapy, which primarily inter-
fere with DNA replication and cell cycle progression (Lord and
Ashworth, 2012). Interestingly, DNA double-strand breaks are
generated as an intermediate when they exert their effect on can-
cer cells. Besides the absence/inactivity of repair proteins, it
needs to be understood whether hyperactivity of the repair pro-
teins, their re-emergence, or overlapping compensatory path-
ways can make cancer cells resistant and account for theChemistry & Biolrelapse. Hence, targeting HR or NHEJ in cancer cells can be a
tool to tackle these emerging problems and is an attractive target
for anticancer treatment.
DNA Double-Strand Break Repair, Cancer, and
Drug Resistance
Delicately synchronized DNA repair pathways play a pivotal role
in protecting a cell against genomic instability and mutations.
Besides, DNA repair pathways play a multifaceted role in cancer
onset, progression, and therapeutic response. It needs to be
taken into consideration that either decreased or increased ac-
tivities of DNA repair proteins can predispose the cells to cancer
(Figure 4). Erroneous or deregulated DNA repair results in chro-
mosomal translocations, genomic rearrangements, and higher
mutation rates, which may provide survival advantages to can-
cer cells (Lieberman, 2008; Powell and Bindra, 2009). Levels of
DNA repair, hyperactivation of a particular branch of DNA repair,
a defective repair pathway, and the ability of drugs to inhibit or
activate DNA repair can dictate a patient’s response to therapy
(Begg et al., 2011). In short, DNA repair pathways are multidi-
mensional regulators of tumorigenesis. Their activation, use,
gain, or loss can determine the survival outcomes of therapy.
It has been suggested that, in neoplasms, defects in one repair
pathway can be compensated by the other, resulting in suc-
cessful cell proliferation and progression of cancer cells, which
also makes them more dependent on the salvage repair
pathway and, hence, vulnerable to certain genotoxic stresses
(Curtin, 2012; Lord and Ashworth, 2012). Upregulated DNA
repair can make cancer cells resistant or cause posttreatment
relapse.
Besides, cancer cells have defects in cell cycle checkpoints
and redox regulation, unlike normal cells. Hence, cancer cells
accumulate more damage, which, in turn, makes repair mecha-
nisms indispensable in several cancers for their growth. Re-
cently, dysregulated redox mechanisms have been exploited
as a target of anticancer therapy. Targeting of Mut T homolog
1 (MTH1, also known as NUDT1), a protein important for sani-
tizing the dNTP pool, selectively eradicates cancer cells while
sparing normal cells. It has been shown that the MTH1 inhibitors
TH588 and (S)-crizotinib are anticancer small-molecule com-
pounds (Gad et al., 2014; Huber et al., 2014).
Therefore, the correlation between cancer and DNA repair
provides a rationale for the use of inhibitors against DNA repair
to sensitize tumors with functional or hyperactive repair activity
in conventional chemotherapy (Figure 5).
HR-Associated Cancer Incidences and Resistance
Several cancer predisposition mutations in HR genes have been
associated with cancers. Germline BRCA1 and BRCA2 muta-
tions have been studied comprehensively and account for
heritable cancers (Figure 4) (Petrucelli et al., 2010). Secondary
mutations at these loci, because of HR defects, can impart resis-
tance to Cisplatin and PARP inhibitors (Helleday, 2010). These
secondary mutations or genetic reversions can restore open
reading frames and result in the re-expression of almost full-
length proteins in cancers (Dhillon et al., 2011). This means
that the efficacy of these inhibitors relies on a concomitant defect
in the HR pathway. Besides, elevation of the HR pathway has
also been correlated with incidences of sporadic breast cancer
(Figure 4) (Mao et al., 2008).ogy 22, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 21
Figure 5. DNA Double-Strand Break Repair,
Drug Resistance in Cancer, and Therapeutic
Implications
DNA repair pathways have a comprehensive
function in oncogenesis and in the response to
therapeutic modalities. Mutations in DSB repair
pathways can result in genomic instability and
higher mutation rates, which may provide a sur-
vival advantage to cancer cells. Absent or impaired
DSB repair pathways can make cancer cells
vulnerable to certain kinds of genotoxic stresses.
On the other hand, upregulation, polymorphisms,
or hyperactivation of DSB repair pathways also
support tumorigenesis and maintenance. De-
pending on the correlation of DNA repair proteins
to oncogenesis, different strategies can be em-
ployed for effective anticancer therapies.
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human cancers, such as pancreatic cancer, breast cancer, soft
tissue sarcoma, and leukemia (Figure 4; Hannay et al., 2007).
An increased repair rate of etoposide-induced damage by
increased RAD51 levels imparts resistance to small-cell lung
cancer cells (Hansen et al., 2003). A direct correlation has been
observed between levels of RAD51 in cancer cells and its
response toward radiation and other DSB-inducing agents (Hel-
leday, 2010). Decreased expression of key HR proteins such
as Mre11, RAD50, and NBS1 has been reported in breast carci-
nomas. Besides, deregulated expression of MRN complex pro-
teins has also been associated with melanoma and ovarian,
colorectal, and head and neck cancer (Figure 4; Mosor et al.,
2006; Zio´1kowska-Suchanek et al., 2013). Among these, deregu-
lated NBS1 expression has been proposed to be a prognostic
marker for metastasis in head and neck cancer and is associated
with the decreased survival of breast carcinoma patients (Yang
et al., 2007).
DNA crosslinking agents such as mitomycin C, cisplatin (cis-
diamminedichloroplatinum[II]), melphalan, etc. are widely used
and considered to be broad-range drugs in cancer therapy (No-
jima et al., 2005). Resistance toward thesemodalities because of
a higher rate of adduct removal is themajor concern for their use.
ERCC1, which plays an important role in interstrand crosslink
(ICL) repair, is used as a prognostic marker for lung, head, and
neck cancer (Vaezi et al., 2011). Furthermore, a strong correla-
tion has been found between the success of chemotherapies us-
ing platinum-based compounds and the expression levels of
ERCC1 in the tumor, making it an attractive target (McNeil and
Melton, 2012). In an interesting study, it has been found that so-
matic inactivation of the FANC-BRCA1 pathway by methylation
acts as a first hit to normal cells in the development of ovarian
cancer and can be treated by cisplatin (Taniguchi et al., 2003).
However, reversal of silenced genes such as FANCF in some
cancer cells results in relapse and resistance to treatment (Helle-
day, 2010). It has been speculated that inhibitors of the Fanconi
anemia pathwaymight render sensitivity of such cancers to ther-
apy (Jenkins et al., 2012). Mutations and polymorphisms in BLM
have been associated with a high risk of colorectal and breast22 Chemistry & Biology 22, January 22, 2015 ª2015 Elsevier Ltd All rights reservedcancer, respectively (Gruber et al., 2002;
Sassi et al., 2013). Another RecQ heli-
case, Werner syndrome (WRN), which, in
addition to its partially redundant functionwith BLM, also possesses an additional 30-50 exonuclease activ-
ity and is important for elongation during replication, has been
found to be overexpressed in hypopharyngeal carcinomas,
which are known for their poor prognosis among head and
neck squamous cell carcinomas (Arai et al., 2011; Sidorova,
2008). These recent reports make these helicases viable thera-
peutic targets (Gupta and Brosh, 2008).
NHEJ-Associated Cancer Incidences and Resistance
NHEJ being a major DSB repair pathway in the mammalian sys-
tem can play a major role in providing resistance to cancer cells
against various radio- and chemotherapeutic agents (Begg et al.,
2011). Overexpression of NHEJ factors or hyperactivation of the
pathway can dictate the turnover of the DSBs produced by
radio- or chemotherapy, which hampers successful therapy.
Drug-resistant cancer stem cells from pediatric brain tumors
have also been reported to have higher levels of repair (Hussein
et al., 2011). It has also been shown that murine breast cancer
cells, which are more resistant to chemotherapy, possessed
reduced levels of gH2AX focus formation after 5 Gy of g radia-
tion, suggesting hyperactive DSB repair, which imparts resis-
tance (Li et al., 2008; Shafee et al., 2008; Zhang et al., 2008).
There are numerous examples implicating NHEJ factors
contributing toward radioresistance. Levels of KU and DNA-
PKcs proteins have been found to be elevated in breast cancer,
gastric cancers, oral squamous cell carcinoma, lung carcinoma,
and esophageal cancer (Figure 4; Beskow et al., 2009; Pucci
et al., 2001; Shintani et al., 2003; Sirze´n et al., 1999). Overexpres-
sion of KU has been documented with higher DNA binding po-
tential in ionization radiation-resistant cancer cells, indicating
higher repair (Frit et al., 1999). Besides the effect on the fate of
radiotherapy outcomes, other modes of cancer treatment are
also affected by NHEJ proteins.
Glucose starvation has been shown to induce oxidative stress
in malignant cells, unlike in normal cells, and can potentially
result in their selective removal. Therefore, the potential of ana-
logs of glucose, such as 2-deoxy-D-glucose, has been explored
for the development of chemotherapy (Simons et al., 2009). It
was found that glucose deprivation could lead to increased
expression of KU, which imparts resistance to otherwise
Table 2. Names of DSB Repair Proteins and Their Inhibitors
DSB Repair
Proteins Repair Pathway
Therapeutically Relevant
Small-Molecule Inhibitor(s) References
ATM HR/NHEJ KU55933 Hickson et al., 2004; Rainey et al., 2008
ATR HR/NHEJ caffeine, VE-821, NU6027 Darbon et al., 2000; Toledo et al., 2011
CHK1 HR UCN-01 Zhao et al., 2002
MRE11 HR mirin Dupre´ et al., 2008
RAD51 HR RI-1, RI-2 Huang et al., 2011; Budke et al., 2012; Budke et al., 2013
RAD54 HR streptonigrin Deakyne et al., 2013
PARP1 SSBR 3-ABA, olaparib, NU1025, etc. Bryant et al., 2005; Farmer et al., 2005; Brenner et al., 2011
ERCC1 SSA/NER/ ICL/MMEJ NSC130813 Jordheim et al., 2013
DNA-PKcs NHEJ wortmannin, NU7026, LY294002 Oliveira et al., 2002; Willmore et al., 2004
Ligase IV NHEJ SCR7, L189 Chen et al., 2008; Srivastava et al., 2012
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because increased levels of reactive oxygen species upon
glucose deprivation in cancer cells may give rise to DSBs, which
can be repaired faster upon KU overexpression, therefore pro-
tecting these cells from DNA damage-induced apoptosis. It
has been demonstrated that enhanced expression of DNA-
PKcs can avert the effects of the anticancer drug Adriamycin
(a Topo II inhibitor and DNA intercalator) in resistant cancer cells
(Shen et al., 1998). Interestingly, it has also been observed that
etoposide-resistant small lung cancer cells have a higher DSB
turnover rate that is accompanied by increased DNA-PKcs
expression (Hansen et al., 2003). Besides, polymorphisms in
XRCC4 and Ligase IV have been reported in breast cancers
(Figure 4; Kuschel et al., 2002). It would be of interest to see
whether these natural polymorphisms can affect the structure
of the protein or rate of DSB catalysis. Because of the key role
of NHEJ in cancer, various studies have suggested that downre-
gulation of NHEJ activity in cancer cells could lead to elevated
sensitivity to radio- and chemotherapeutic agents, making it a
prime chemotherapeutic target.
DSB Repair as a Target for Anticancer Therapy
Inhibitors that can act via modulating DNA repair to facilitate the
death of cancer cells have been developed. In principle, the
success of inhibition of DNA repair pathways in therapy de-
pends on the selection of the protein target. In general, a drug
target would be a repair protein that is directly involved in onco-
genesis or displays synthetic lethal interactions with the
affected repair protein. Repair proteins that might be directly
involved in tumorigenesis would be either overexpressed or hy-
peractive or possess aberrant activity because of mutations. On
the other hand, synthetic lethal interactions can be helpful to
specifically target cancer cells in which DNA repair genes are
silenced, causing overdependence on another repair pathway
for survival (Morandell and Yaffe, 2012). Therefore, two genes
are synthetic lethal when silencing either of them alone can sup-
port cell viability, whereas inhibiting both leads to cell death
(Kaelin, 2005; Shaheen et al., 2011). Therefore, it is of immense
importance to identify repair proteins whose expression or use
differ quantitatively or qualitatively in cancer cells compared
with normal cells. Some inhibitors have been reported that are
designed specifically against any DSB repair protein and haveChemistry & Biolbeen tested for their potential to be used as chemotherapeutic
agents (Table 2).
Inhibitors of Homologous Recombination
Inhibitors of homologous recombination are the most well stud-
ied of all DNA repair inhibitors. Mirin is the most famous example
of an HR inhibitor that was developed against endonuclease ac-
tivity of MRE11 (Dupre´ et al., 2008). However, because MRE11
also acts upstream of NHEJ, it may not be specific to HR. This
makes it difficult to determine the mechanism responsible for
sensitization of cancer cells and, therefore, the pathway that is
inhibited for the greatest clinical benefit is uncertain.
For a long time, caffeine was the only available ATR and ATM
inhibitor (Cortez, 2003). Caffeine, in preclinical trials, provided
positive radiosensitization effects but was compromised in
terms of potency and specificity (Darbon et al., 2000). Specific
ATR inhibitors (VE-821 and NU6027) have been identified based
on cell-based screens and found to be especially toxic to cells
deficient in p53 (Toledo et al., 2011). NU6027 also inhibited
RAD51 focus formation (indicative of HR suppression), leading
to synthetic lethality with base excision repair inactivation (Peas-
land et al., 2011). Recently, inhibitors have been designed
against RAD51 (Huang et al., 2011). RI-1 covalently binds to
the surface of RAD51, thereby reducing its focus formation,
and has been found to potentiate the action of crosslinking
agents (Budke et al., 2013). Both RI-1 and its optimized version,
RI-2, can inhibit homologous recombination in human cells, pro-
moting single-strand annealing (Budke et al., 2012, 2013).
Although it has shown promising results ex vivo, further studies
dealing with pharmacologic evaluation and in vivo studies have
to be performed. The observation of a synthetic lethal interaction
between RAD52 and BRCA2 indicated that inhibitors of RAD51
paralogs can also be developed for selective targeting of
BRCA2-deficient tumors (Deakyne et al., 2013; Feng et al.,
2011; Lok and Powell, 2012).
HR has also been targeted by inhibition of the ATM–CHK2 or
ATR–CHK1 pathways. The first selective ATM inhibitor,
KU55933, blocked ionization radiation (IR)-induced, ATM-
dependent phosphorylation and sensitized cancer cells to IR
and topoisomerase inhibitors (Hickson et al., 2004; Rainey
et al., 2008). However, this and other inhibitors are in the early
stages of development. Recently, a nonspecific staurosporin
analog, UCN-01, has been shown to be a potent CHK1 inhibitorogy 22, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 23
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clinical trials because of its limited bioavailability, poor pharma-
cokinetics, and toxicity. Although other CHK1 inhibitors have
been studied, they were not tested further because of their
adverse side effects. Small-molecule inhibitors of the human
RecQ helicases BLM (ML216) and WRN (NSC19630) have also
been described (Aggarwal et al., 2011; Nguyen et al., 2013).
Recently, using in silico screening, an ERCC1 inhibitor,
NSC130813, has been reported that synergizes the effect of
cisplatin and mitomycin C (Jordheim et al., 2013).
A landmark approach based on synthetic lethality became
popular based on the finding that inhibition of PARP1 is particu-
larly lethal in BRCA1/2-null ovarian or breast tumors with no side
effects (Bryant et al., 2005; Farmer et al., 2005). BRCA1/PARP
combination treatment has become the paradigm for a new
class of rational cancer therapy. The PARP1 inhibitor olaparib
has shown very promising results in phase II clinical trials and
supports the concept of synthetic lethality in BRCA1-null breast
cancers. Currently, enrollments have been initiated for phase III
clinical trials to test it as a monotherapy in BRCA-mutated
ovarian cancer patients following first-line platinum-based che-
motherapy (ClinicalTrials.gov identifier NCT01844986). Another
trial has also been initiated to test its effect on BRCA-mutated,
high-risk HER2 negative primary breast cancer patients
(ClinicalTrials.gov identifier NCT02032823). Besides ovarian
and breast cancers, the efficacy of PARP1 inhibitors is also being
evaluated in non-small lung and gastric cancers (ClinicalTrials.
gov identifiers NCT01924533 and NCT01788332, respectively).
Studies also revealed that PARP1 inhibition can selectively
sensitize cells with TMPRSS2:ERG fusion in ETS-positive pros-
tate cancers (Brenner et al., 2011). In an interesting study, it
has also been shown that mild hyperthermia induces degrada-
tion of BRCA2 and abolishes RAD51-BRCA2 focus formation,
leading to inhibition of HR. Therefore, a mild increase in temper-
ature can make HR-proficient cells sensitive to PARP1 inhibitors
(Krawczyk et al., 2011). Hence, remarkable efforts have been
made in the generation of potent HR inhibitors with limited side
effects (Carvalho and Kanaar, 2014). The success of develop-
ment of an improved, broad-spectrum drug for cancer exploiting
HR also relies on our broader understanding of the pathway.
With a better understanding of regulatory circuits and the deci-
sive steps of HR, better drug targets can be identified. Therefore,
HR still remains a potentially viable therapeutic target.
Inhibitors of Nonhomologous DNA End Joining
Despite being themajor DNAdouble-strand break repair pathway
in the mammalian system, little is known about inhibitors of core
NHEJ proteins such as the KU70/80 complex, Artemis, Ligase IV/
XRCC4, Pol m, and Pol l. Among all NHEJ proteins, until recently,
only DNA-PKcs has been exploited as a target for anticancer ther-
apy (Table 2). One of the first inhibitors of DNA-PKcs was wort-
mannin, which is a sterol-like fungal metabolite. Wortmannin
does not selectively inhibit DNA-PKcs. Instead, it acts as a pan
PI3K inhibitor (Oliveira et al., 2002). There have been extensive
studies related to its effect on end joining to define the role of
DNA-PKcs in NHEJ (Budman et al., 2007; Smith et al., 2001).
Various groups have demonstrated not only its radiosensitizing
effect but also its ability to potentiate the effect of ionization radi-
ation in cancer cell lines (Price and Youmell, 1996). A more potent
derivative of quercetin, LY294002, has also been shown to24 Chemistry & Biology 22, January 22, 2015 ª2015 Elsevier Ltd All rpossess similar properties (Rosenzweig et al., 1997). Although
promising, the possibility of these compounds acting in an off-
target manner restricts their use as effective cancer therapeutic
agents. Recently, NU7026 has been reported to be a very selec-
tive and potent DNA-PK inhibitor (Table 2;Willmore et al., 2004). It
has been shown to be at least 60-foldmore effective towardDNA-
PKcs than other PI3Ks and was almost insensitive toward ATM
and ATR kinases. Its radiosensitization and end joining inhibitory
action were alsowell studied (Veuger et al., 2003). Various studies
have highlighted its role in potentiating the effects of IR and eto-
poside (Willmore et al., 2004).
No small-molecule inhibitors for KU proteins have been re-
ported thus far. However, their therapeutic potential has been
explored by the use of antisense oligonucleotides, RNA interfer-
ence, and blocking peptides (Ayene et al., 2005; Belenkov et al.,
2002).
The proteins discussed above play a role in the initial recogni-
tion steps of NHEJ. However, inhibition at the early stage of
damage recognition could divert the unrepaired DSBs to the
error-prone alternative NHEJ pathway. Alternatively, targeting
a protein involved in the final stage of NHEJ, such as Ligase IV,
could block this, leading to accumulation of DNA breaks, which
can be lethal to cancer cells.
Recently, the targeting of Ligase IV was explored for investi-
gating its anticancer therapeutic value. L189 was developed as
a potential Ligase IV inhibitor. However, it blocked the activity
of all three ligases, Ligase I, Ligase III, and Ligase IV (Chen
et al., 2008). Until recently, the major challenge for designing in-
hibitors against Ligase IV was the lack of structural information.
Recently, based on homology modeling for the DNA binding
domain of Ligase IV, several potential Ligase IV inhibitors were
investigated, and SCR7 was identified as the most potent inhib-
itor of end joining (Srivastava et al., 2012). SCR7 could inhibit
NHEJ both in vitro and ex vivo in a Ligase IV-dependent manner.
Inhibition of NHEJ in cancer cells resulted in the accumulation of
unrepaired DSBs, which eventually led to cytotoxicity. Its thera-
peutic potential was evaluated in different mouse tumor models,
and three out of four tumor models tested showed significant tu-
mor regression. More importantly, it has been observed that
SCR7 could potentiate the effects of radio- and chemotherapy
when coadministered (Srivastava et al., 2012). Therefore,
SCR7 showed promising results in preclinical studies. However,
its therapeutic potential has to be evaluated further. Although it
acts in a target-specific manner, it has a considerably higher
inhibitory concentration 50 value, emphasizing the need for its
modification for drug optimization.
In conclusion, the DNA repair machinery can provide a growth
advantage or resistance to malignant cells in humans. These
nononcogene addictions provide a challenging yet attractive
target for the development of effective cancer therapy. Signifi-
cant efforts have been undertaken both in terms of identifying
the target and development of DNA repair inhibitors. Importantly,
exploring the differences with respect to the utility of repair path-
ways or their mechanistic differences in cancer versus normal
cells would help to develop effective, less toxic DNA repair inhib-
itors to target cancer.
Future Directions
The realization that DNA repair pathways, which guard the
genome against DNA-damaging agents, can be exploited asights reserved
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Reviewthe vital targets for treating cancers is very encouraging.
Because certain DNA repair pathways/proteins are upregulated
in specific cancers or radio- or chemoresistant cancers, it makes
them ideal targets for designing inhibitors without affecting the
normal cells. Therefore, strategies utilizing the DNA repair path-
ways as targets for anticancer treatment can result in the devel-
opment of potent candidates for therapeutics. Making use of our
knowledge about synthetic lethal interactions, which enable
cancer cells to survive even when one branch of repair pathway
is affected, and translating them into therapies can be pivotal for
the success of future anticancer treatments. Targeting these
synthetic lethal interactions can equip us to specifically target
cancer cells.
The combination of genotoxic agents such as radiation along
with repair inhibitors can effectively sensitize cancer cells. Most
importantly, it can also bring down the effective dosage of radi-
ation and chemotherapeutic agents, providing solutions to many
resistant cancers and associated side effects.
Some of the most challenging aspects of developing inhibitors
against DNA repair proteins are attributed to tumor heterogeneity,
variable levels of DNA repair proteins in different types of tumors,
and their effects on normal cells. This can partly be addressed by
understanding the cause of oncogenesis and the advantages
attributed to cancer and cancer stem cells by hyperactive DNA
repair machineries. A localized increase in specific DNA damage
followed by inhibition of a DNA repair pathway can immensely
affect the survival outcome of cancer cells. Besides, a DNA repair
protein whose indispensability is skewed toward cancer can be
targeted for selective elimination in neoplastic cells.
The area of development of DNA repair inhibitors has just
started to expand, and extensive studies need to be done to
achieve a therapeutic strategy that can effectively and selec-
tively kill cancer cells while sparing normal cells.ACKNOWLEDGMENTS
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